Premium
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Author(s) -
Dömling Alexander,
Holak Tad A.
Publication year - 2014
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201307906
Subject(s) - immunotherapy , medicine , cancer , cancer immunotherapy , disease , antibody , cancer therapy , cancer treatment , cause of death , immunology , oncology
No other cancer therapy target class caused more excitement than the programmed death‐1 (PD‐1) pathway related. Antibodies against PD‐1 and PD‐1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a “clinically manageable” disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom